series-c-plus
Stage
1
Investors
About
Oxyrane is a biopharmaceutical company focused on developing enzyme replacement therapies (ERTs) for lysosomal storage diseases, particularly those affecting the central nervous system. The company utilizes a proprietary glyco-engineering yeast platform to produce enzymes with enhanced cellular uptake and efficacy.
Explore Oxyrane's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.